Trial Profile
Proof-of-concept Multicentre, Prospective, Randomised, Open-label and Parallel Group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5 mg Six-monthly in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ANABRAQ
- Sponsors Ipsen
- 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 14 Nov 2014 New source identified and integrated: European Clinical Trials Database record.
- 30 Sep 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.